These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Assay interaction between oxaprozin and phenytoin. Patel T; Radomski KM; Chandler MH Ann Pharmacother; 1997 Feb; 31(2):254. PubMed ID: 9034434 [No Abstract] [Full Text] [Related]
7. The transsynovial distribution of oxaprozin. Kurowski M; Thabe H Agents Actions; 1989 Jun; 27(3-4):458-60. PubMed ID: 2801338 [TBL] [Abstract][Full Text] [Related]
9. Inverse nonlinear pharmacokinetics of total and protein unbound drug (oxaprozin): clinical and pharmacokinetic implications. Karim A J Clin Pharmacol; 1996 Nov; 36(11):985-97. PubMed ID: 8973987 [TBL] [Abstract][Full Text] [Related]
10. Oxaprozin-Loaded Lipid Nanoparticles towards Overcoming NSAIDs Side-Effects. Lopes-de-Araújo J; Neves AR; Gouveia VM; Moura CC; Nunes C; Reis S Pharm Res; 2016 Feb; 33(2):301-14. PubMed ID: 26350105 [TBL] [Abstract][Full Text] [Related]
11. Oxaprozin: kinetic and dynamic profile in the treatment of pain. Kean WF Curr Med Res Opin; 2004 Aug; 20(8):1275-7. PubMed ID: 15324530 [TBL] [Abstract][Full Text] [Related]
12. The elimination profiles of oxaprozin in equine urine and serum after a 4.8-g dose. Marland A; Sarkar P; Leavitt R; Lee-Ruff E; Ramnauth J J Anal Toxicol; 1999; 23(4):242-6. PubMed ID: 10445486 [TBL] [Abstract][Full Text] [Related]